Markets

Stock Alert: Verona Pharma Trading 85% Higher

(RTTNews) - Shares of clinical-stage biopharmaceutical company focused on respiratory diseases Verona Pharma plc (VRNA) are surging more than 85% friday morning at $8.72 after the company said it has raised approximately $200 million in private placement to fund its phase III study dubbed ENHANCE in chronic obstructive pulmonary disease (COPD).

The trials are planned to start later this year.

VRNA is currently trading at $8.38. It has traded in the range of $2.01- $12.89 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VRNA

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More